Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children
Tóm tắt
The highly sensitive gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay permits the investigation of the role of cell-mediated immunity (CMI) in the protection of young children against influenza. Preliminary studies of young children confirmed that the IFN-γ ELISPOT assay was a more sensitive measure of influenza memory immune responses than serum antibody and that among seronegative children aged 6 to <36 months, an intranasal dose of 107fluorescent focus units (FFU) of a live attenuated influenza virus vaccine (CAIV-T) elicited substantial CMI responses. A commercial inactivated influenza virus vaccine elicited CMI responses only in children with some previous exposure to related influenza viruses as determined by detectable antibody levels prevaccination. The role of CMI in actual protection against community-acquired, culture-confirmed clinical influenza by CAIV-T was investigated in a large randomized, double-blind, placebo-controlled dose-ranging efficacy trial with 2,172 children aged 6 to <36 months in the Philippines and Thailand. The estimated protection curve indicated that the majority of infants and young children with ≥100 spot-forming cells/106peripheral blood mononuclear cells were protected against clinical influenza, establishing a possible target level of CMI for future influenza vaccine development. The ELISPOT assay for IFN-γ is a sensitive and reproducible measure of CMI and memory immune responses and contributes to establishing requirements for the future development of vaccines against influenza, especially those used for children.
Từ khóa
Tài liệu tham khảo
Anthony, D. D., H. Valdez, A. B. Post, N. L. Carlson, P. S. Heeger, and P. V. Lehmann. 2002. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. Clin. Immunol.103:264-276.
Ashkenazi, S., A. Vertruyen, J. Arístegui, S. Esposito, D. D. McKeith, T. Klemola, J. Biolek, J. Kühr, T. Bujnowski, D. Desgrandchamps, S. M. Cheng, J. Skinner, W. C. Gruber, B. D. Forrest, and the CAIV-T Study Group. 2006. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza virus vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J.25:870-879.
Bachmann, M. F., T. M. Kundig, H. Hengartner, and R. M. Zinkernagel. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without ‘memory T cells’? Proc. Natl. Acad. Sci. USA94:640-645.
Belshe, R. B. 2004. Current status of live attenuated influenza virus vaccine in the US. Virus Res.103:177-185.
Belshe, R. B., K. M. Edwards, T. Vesikari, S. V. Black, R. E. Walker, M. Hultquist, G. Kemble, E. M. Connor, and the CAIV-T Comparative Efficacy Study Group. 2007. Live attenuated versus inactivated influenza virus vaccine in infants and young children. N. Engl. J. Med.356:685-696.
Belshe, R. B., W. C. Gruber, P. M. Mendelman, I. Cho, K. Reisinger, S. L. Block, J. Wittes, D. Iacuzio, P. Piedra, J. Treanor, J. King, K. Kotloff, D. I. Bernstein, F. G. Hayden, K. Zangwill, L. Yan, and M. Wolff. 2000. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr.136:168-175.
Belshe, R. B., W. C. Gruber, P. M. Mendelman, H. B. Mehta, K. Mahmood, K. Reisinger, J. Treanor, K. Zangwill, F. G. Hayden, D. I. Bernstein, K. Kotloff, J. King, P. A. Piedra, S. L. Block, L. Yan, and M. Wolff. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis.181:1133-1137.
Belshe, R. B., P. M. Mendelman, J. Treanor, J. King, W. C. Gruber, P. Piedra, D. I. Bernstein, F. G. Hayden, K. Kotloff, K. Zangwill, D. Iacuzio, and M. Wolff. 1998. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med.338:1405-1412.
Bernstein, E., D. Kaye, E. Abtruyn, P. Gross, and M. Dorfman. 1999. Immune response to influenza vaccination in a large healthy elderly population. Vaccine17:82-94.
Blazevic, V., C. M. Trubey, and G. M. Shearer. 2000. Comparison of in vitro immunostimulatory potential of live and inactivated viruses. Hum. Immunol.61:845-849.
Boon, A. C. M., E. Fringuelli, Y. M. F. Graus, R. A. M. Fouchier, K. Sintnicolaas, A. M. Iorio, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus. 2002. Influenza A virus specific T cell immunity in humans during aging. Virology299:100-108.
Carson, M. M., D. W. Spady, J. A. Beeler, M. P. Krezolek, S. Audet, and H. F. Pabst. 2005. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII® at 15 months of age and antibody levels at 27 months of age. Vaccine23:3247-3255.
The 1998-99 WHO influenza reagent kit for the identification of influenza isolates. 1998
Centers for Disease Control and Prevention. 2001. Update: influenza activity—United States and worldwide, 2000-01 season, and composition of the 2001-02 influenza vaccine. MMWR Morb. Mortal. Wkly. Rep.50:466-470.
Cheng, S. M., R. Vainionpää, P. Zhao, F. Li, A. Hu, B. Forrest, and R. Rappaport. 2004. Detection of influenza B in clinical specimens: comparison of high throughput RT-PCR and culture confirmation. Virus Res.103:85-90.
Clover, R. D., S. Crawford, W. P. Glezen, L. H. Taber, C. C. Matson, and R. B. Couch. 1991. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J. Infect. Dis.163:300-304.
Cox, R. J., K. A. Brokstad, and P. Ogra. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live attenuated influenza vaccines. Scand. J. Immunol.59:1-15.
Edwards, K. M., W. D. Dupont, M. K. Westrich, W. D. Plummer, Jr., P. S. Palmer, and P. F. Wright. 1994. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis.169:68-76.
Evans, A. E., R. L. Simmons, R. D. Ferris, S. K. Hasell, E. Letley, and D. S. Freestone. 1979. Antibody responses to vaccination with WRL 105 strain live influenza vaccine in previously vaccinated and unvaccinated volunteers. J. Hyg. (London)82:489-495.
Fox, J. P., M. K. Cooney, C. E. Hall, and H. M. Foy. 1982. Influenza virus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am. J. Epidemiol.116:228-242.
Foy, H. M., M. K. Cooney, R. McMahan, E. Bor, and J. T. Grayston. 1971. Single-dose monovalent A2/Hong Kong influenza vaccine. Efficacy 14 months after immunization. JAMA217:1067-1071.
Gray, D., and P. Matzinger. 1991. T cell memory is short-lived in the absence of antigen. J. Exp. Med.174:969-974.
Guidotti, L. G., and F. V. Chisari. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol.19:65-91.
Guthrie, T., C. G. L. Hobbs, V. Davenport, R. E. Horton, R. S. Heyderman, and N. A. Williams. 2004. Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J. Infect. Dis.190:1927-1935.
Habermehl, P., A. Lignitz, M. Knuf, H.-J. Schmitt, M. Slaoui, and F. Zepp. 1999. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine17:669-674.
He, X.-S., M. Draghi, K. Mahmood, T. H. Holmes, G. W. Kemble, C. L. Dekker, A. M. Arvin, P. Parham, and H. B. Greenberg. 2004. T cell-dependent production of IFN-γ by NK cells in response to influenza A virus. J. Clin. Investig.114:1812-1819.
Heikkinen, T., H. Silvennoinen, V. Peltola, T. Ziegler, R. Vainionpää, T. Vuorinen, L. Kainulainen, T. Puhakka, T. Jartti, P. Toikka, P. Lehtinen, T. Routi, and T. Juven. 2004. Burden of influenza in children in the community. J. Infect. Dis.190:1369-1373.
Helms, T., B. O. Boehm, R. J. Asaad, R. P. Trezza, P. V. Lehmann, and M. Tary-Lehmann. 2000. Direct visualization of cytokine-producing recall-antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J. Immunol.164:3723-3732.
Herremans, T. M. P. T., J. H. J. Reimerink, A. M. Buisman, T. G. Kimman, and M. P. G. Koopmans. 1999. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J. Immunol.162:5011-5018.
Lalvani, A., R. Brookes, S. Hambleton, W. J. Britton, A. V. S. Hill, and A. J. McMichael. 1997. Rapid effector function in CD8+ memory T cells. J. Exp. Med.186:859-865.
Lee, M. S., K. Mahmood, L. Adhikary, M. J. August, J. Cordova, I. Cho, G. Kemble, K. Reisinger, R. E. Walker, and P. M. Mendelman. 2004. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J.23:852-856.
Longini, I. M., and M. E. Halloran. 2005. Strategy for distribution of influenza vaccine to high-risk groups and children. Am. J. Epidemiol.161:303-306.
McElhaney, J. E., J. W. Hooton, N. Hooton, and R. C. Bleackley. 2005. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine23:3294-3300.
McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Beare. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med.309:13-17.
Mendelman, P. M., R. Rappaport, I. Cho, S. Block, W. Gruber, M. August, D. Dawson, J. Cordova, G. Kemble, K. Mahmood, G. Palladino, M. S. Lee, A. Razmpour, J. Stoddard, and B. D. Forrest. 2004. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against A/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J.23:1053-1055.
Müllbacher, A., M. Lobigs, M. Alsharifi, and M. Regner. 2006. Cytotoxic T-cell immunity as a target for influenza vaccines. Lancet Infect. Dis.6:255-256.
Murasko, D. M., E. D. Bernstein, E. M. Gardner, P. Gross, G. Munk, S. Dran, and E. Abrutyn. 2002. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol.37:427-439.
National Institutes of Health. 1973. Specific immunity in influenza B. Summary of influenza workshop III. J. Infect. Dis.127:220-236.
Neuzil, K. M., Y. Zhu, M. R. Griffin, K. M. Edwards, J. M. Thompson, S. J. Tollefson, and P. F. Wright. 2002. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J. Infect. Dis.185:147-152.
Nichol, K. L., P. M. Mendelman, K. P. Mallon, L. A. Jackson, G. J. Gorse, R. B. Belshe, W. P. Glezen, and J. Wittes for the Live Attenuated Influenza Virus Vaccine in Healthy Adults Trial Group. 1999. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA282:137-145.
Ohmit, S. E., J. C. Victor, J. R. Rotthoff, E. R. Teich, R. K. Truscon, L. L. Baum, B. Rangarajan, D. W. Newton, M. L. Boulton, and A. S. Monto. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med.355:2513-2522.
Ota, M. O. C., J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, H. Whittle, P.-H. Lambert, K. P. W. J. McAdam, C.-A. Siegrist, and A. Marchant. 2004. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine22:511-519.
Potter, C. W., and J. S. Oxford. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull.35:69-75.
Potter, C. W., R. Jennings, K. Nicholson, D. A. Tyrrell, and K. G. Dickinson. 1977. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J. Hyg. (London)79:321-332.
Powers, D. C., B. R. Murphy, L. F. Fries, W. H. Adler, and M. L. Clements. 1992. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J. Am. Geriatr. Soc.40:163-167.
Prentice, R. L. 1989. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med.8:431-440.
Reichert, T. A., N. Sugaya, D. S. Fedson, W. P. Glezen, L. Simonsen, and M. Tashiro. 2001. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med.344:889-896.
Rennels, M. B., H. C. Meissner, and Committee on Infectious Diseases. 2002. Technical report: reduction of the influenza burden in children. Pediatrics110:e80. www.pediatrics.org/cgi/content/full/110/6/e80 .
Samdal, H. H., H. Bakke, F. Oftung, J. Holst, I. L. Haugen, G. E. Korsvold, A. C. Kristoffersen, G. Krogh, K. Nord, R. Rappuoli, A. K. Berstad, and B. Haneberg. 2005. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Hum. Vaccines1:85-90.
Saurwein-Teissl, M., K. Zisterer, T. L. Schmitt, R. Gluck, S. Cryz, and B. Grubeck-Loebenstein. 1998. Whole virus influenza activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin. Exp. Immunol.114:271-276.
Speiser, D. E., M. J. Pittet, P. Guillaume, N. Lubenow, E. Hoffman, J. C. Cerottini, and P. Romero. 2004. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-γ ELISPOT assays for patient immune monitoring. J. Immunother.27:298-308.
Svahn, A., A. Linde, R. Thorstensson, K. Karlén, L. Andersson, and H. Gaines. 2003. Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus. J. Immunol. Methods277:17-25.
Tam, J. S., M. R. Capeding, L. C. Lum, T. Chotpitayasunondh, Z. Jiang, L. M. Huang, B. W. Lee, Y. Qian, R. Samakoses, S. Lolekha, K. P. Rajamohanan, S. N. Narayanan, C. Kirubakaran, R. Rappaport, A. Razmpour, W. C. Gruber, B. D. Forrest, and the Pan-Asian CAIV-T Pediatric Efficacy Trial Network. 2007. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr. Infect. Dis. J.26:619-628.
Treanor, J., and P. F. Wright. 2003. Immune correlates of protection against influenza in the human challenge model. Dev. Biol. (Basel)115:97-104.
Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol.13:251-276.
Vernacchio, L., H. Bernstein, S. Pelton, C. Allen, K. MacDonald, J. Dunn, D. D. Duncan, G. Tsao, V. LaPosta, J. Eldridge, S. Laussucq, D. M. Ambrosino, and D. C. Molrine. 2002. Effect of monophosphoryl lipid A (MPL®) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine20:3658-3667.
Vesikari, T., D. M. Fleming, J. F. Arístegui, A. Vertruyen, S. Ashkenazi, R. Rappaport, J. Skinner, M. K. Saville, W. C. Gruber, B. D. Forrest, and the CAIV-T Pediatric Day Care Clinical Trial Network. 2006. Safety, efficacy, and effectiveness of live attenuated, trivalent influenza vaccine against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics118:2298-2312.
Vesikari, T., A. Karvonen, T. Korhonen, K. Edelman, R. Vainionpää, A. Salmi, M. K. Saville, I. Cho, A. Razmpour, R. Rappaport, R. O'Neill, A. Georgiu, W. Gruber, P. M. Mendelman, B. Forrest, and the CAIV-T Transmission Study Group. 2006. A randomized, double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr. Infect. Dis. J.25:590-595.
World Health Organization. 2001. Recommended composition of influenza virus vaccines for use in the 2001-2002 season. Wkly. Epidemiol. Rec.76:58-61.